HK Innoen 'K-Cab', Obtains Approval for Oral Disintegrating Tablet Product License

HK Inno.N 'K-CAB Orally Disintegrating Tablet' BI

[Asia Economy Reporter Chunhee Lee] HK Innoen is expanding its market by launching an orally disintegrating tablet (ODT) formulation of the gastroesophageal reflux disease (GERD) drug 'K-CAB' (active ingredient 'Tegoprazan').

On the 11th, HK Innoen announced that 'K-CAB Orally Disintegrating Tablet 50mg' has received final approval from the Ministry of Food and Drug Safety. The ODT formulation can be taken by dissolving in the mouth without the need to drink water separately. This offers significant convenience for patients who have difficulty swallowing pills or cannot drink water. As the patient population eligible for prescription expands, it is expected to contribute to an increase in K-CAB's prescription performance.

Currently, K-CAB continues its growth trend, surpassing 100 billion KRW in outpatient prescription sales with the single formulation 'K-CAB Tablet 50mg' alone. HK Innoen plans to launch the ODT formulation within the first half of this year, while accelerating growth by adding new indications for K-CAB Tablet 50mg based on the Phase 3 clinical trial results of K-CAB's 'maintenance therapy after GERD treatment' announced at the end of last year, and applying for approval of a new item, K-CAB Tablet 25mg.

An HK Innoen official stated, "Once K-CAB Orally Disintegrating Tablet is launched in the first half of this year, it will provide more diverse options for both medical professionals and patients, positively impacting prescription performance," adding, "We plan to steadily continue research on indication expansion, differentiated clinical trials, and development of various formulations to further solidify K-CAB's market position."

This content was produced with the assistance of AI translation services.